



Advancing Research. Improving Lives.™

Research Center Update

July 2023



Mitch Machtay, M.D.,
NRG Deputy Chair for Research/Chief Scientific Officer
Endowed Professor and Associate Dean for Clinical Oncology Research, Penn State



@NRGOnc



NRG Oncology



Reminder: Fall 2023 Call for Application for Membership to Committees

NRG Research Center

Core Cte's

- Hlth Disparities
- CA control
- Pt Outcomes
- Nursing/cRA's
 - Rad Onc
 - Med Onc
 - Surg Onc
 - Imaging
- Trnslational Sci.
 - Pathology

Lung

H&N

Breast

GYN

Dev. Ther.

GI

CNS

GU

Note: GYN, GI and DT have formal subcommittees. Other committees have 'working groups'

Ovary

DT-GYN

Colorectal

Non-CRC

DT - non-GYN

Corpus

Cervix

Rare GYN

Center for Innovations
Radiation Oncology

Ancillary
Projects

Selected NRG Published Highlights 1st Half 2023



Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial

a

b

THE LANCET Oncology

c

Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY • BIOLOGY • PHYSICS

d

Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

e



JOURNAL of the NATIONAL CANCER INSTITUTE

f

Ten-year Update: NRG Oncology/NSABP B-42 Randomized Trial: Extended Letrozole Therapy in Early-stage Breast Cancer

JAMA Oncology


g

Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine
Phase 3 Results of NRG Oncology/RTOG 0631

*a*Krauss DJ; *b* Michalski J; *c* Mileschkin LR; *d*Gondi V; *e*Eskander RN; *f*TMamounas E; *g*Ryu S

NRG Protocol Development

Since birth of NRG (3/1/2014): 83 CTEP; 10 NCORP; + 7 Intergroup Co-led (Grand Total = 100)



New NRG Trials and their Themes: 1st Half 2023



	Study Theme	Gender Based	M0 (or Oligo-M1)	Novel Bio-marker	Novel RT/ Surg	QOL/ PRO	Rare Tumor
EAY191-N2	ComboMATCH: Phase II Fulvestrant and Binimetinib for HR+ metastatic breast CA with NF1 mutation/del.	✓		✓			✓
EAY191-N4	ComboMATCH: Phase IIR Selumetinib+/- Olaparib for recurrent Ovarian or Endometrial CA with Ras pathway mutation.	✓		✓			✓
GY028	Phase IB – IIR: Megace +/- Ipatasertib for recurrent/metastatic endometrial CA.	✓					
BR008	Phase III Radiation vs. no Radiation for 'low risk' HER2 positive breast CA.	✓	✓	✓	✓	✓	
LU008	Phase III Standard chemoradiation vs. SBRT followed by chemoradiation for selected stage III NSCLC.		✓		✓	✓	

EAY191 / ComboMATCH !

Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

STATUS: ACTIVE

<https://ecog-acrin.org/clinical-trials/eay191-combomatch/>




- EAY 191-N2: Fulvestrant + Binimetinib in HR+ Breast CA with NF1 mutation/deletion
- EAY 191-N4: Selumetinib + Olaparib in GYN cancers with RAS pathway mutations
- EAY 191-E4: Paclitaxel + Nilotinib in cancers resistant to prior taxane therapy
- EAY 191-S3: Paclitaxel + Ipatasertib in cancers with AKT mutations

NCTN Goal: ~20 active ComboMATCH studies at any given time

RT Technology: NRG Lung Trial LU-008 Activated!

Eligibility

- Stage III (or N+ stage II)
- Inoperable
- Primary tumor < 7 cm
 - ≥ 2 cm from node(s)
- PS 0-2
- Eligible for post-CRT immunotherapy



Based on a phase I/II study of 55 pts (NCT03141359)

With median f/u of 13.8 mo. there are only 2 regional failures and 0 local failures

(Heinzerling, ASCO 2020, Pract Radiat Oncol 2023)

RT Technology: NRG Brain Met BN009 Relunched!

Eligibility

- Recurrent brain metastases
- Prior radiosurgery
- New met velocity rate >4 per year.
- Lung, breast, melanoma, GI or renal CA

Stratify

- Velocity of new BM's
- Immunotherapy use
- DS-GPA score

R

Salvage
radiosurgery

Hippocampal-
Sparing whole brain
RT (plus **optional**
SRS boost)




Randomization is 1:1

1^o endpoint: 1-yr Neurologic Death Rate

Sample Size: 350 pts

NRG Developing Trials – Currently N=28

- Brain: 3
- Breast: 1 (1 NCI-approved)
- GI: 2
- GU: 3 (1 NCI-approved)
- GYN: 5 (2 NCI-approved)
- DT GYN 2 (2 NCI-approved)
- H&N : 5 (2 NCI-approved)
- DT Combo-Match 2 (1 NCI-approved)
- NCORP: 5 (2 NCI approved with R01)



Selected NRG Research Center Projects

- Preparing 2024 NRG Grant.
- Advancing Themes:
 - ‘Right-sizing’ Intensity of Therapy
 - Optimizing Diversity and Inclusion
 - ‘Curing’ Oligometastatic Cancer
 - Developing new ComboMATCH arms
- Organizing Working Groups in each Committee
- Streamlining:
 - Protocol eligibility requirements
 - Pragmatic designs
 - Modality QA reviews
- Novel Ancillary Projects, e.g. AI discovery and validation



Ancillary Projects (AP's)

Thank you to our top APC 'Peer Reviewers'

- Steve Braunstein (UCSF)
- Paul Brown (Mayo)
- Steve Chang (Henry Ford)
- Stephen Chun (MDAH)
- Paul DiSilvestro (Women & Infants)
- Christina Henson (Oklahoma U)
- Sophia Kamran (MGH)
- Bridget Koontz (GenesisCare/ECU)
- Simon Lo (Univ. Wash.)
- Rimas Lukas (Northwestern)
- Nitin Ohri (Einstein/Montefiore)
- Michael Vogelbaum (Moffitt)
- Trisha Wise-Draper (U Cincinnati)

apc@nrgoncology.org



Steven Waggoner, MD

APC Chair



Suzanne Baldwin
APC Admin Manager


Thank you for Joining our NRG Meeting!

Questions,
including PI requests to attend RSC meeting (Wed. 7/26)

- Mitch Machtay: mmachtay@pennstatehealth.psu.edu
- Ronnie Alvarez: Ronald.Alvarez@vumc.org
- Jame Abraham: abrahaj5@ccf.org

Thank you to the 3 Research Centers in
Pennsylvania, Led by:

- Nancy Soto
- Kia Neff
- Francy Fonzi



Nancy Soto, NRG

